3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Warts
1
Virus Diseases
1
Skin Diseases, Viral
1
Skin Diseases, Infectious
1
Skin Diseases
1
Sexually Transmitted Diseases, Viral
1
Sexually Transmitted Diseases
1
Papillomavirus Infections
1
Condylomata Acuminata
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
6
Radiotherapy, Intensity-Modulated
5
Cisplatin
5
Carboplatin
5
Papillomavirus Vaccines
4
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
4
artesunic acid
3
artemisinin
3
Paclitaxel
3
Human Papillomavirus Recombinant Vaccine nonavalent
3
artenimol
2
Vaccines, Synthetic
2
Taxes
2
Radiation
2
Imiquimod
2
GX-188 vaccine
2
Docetaxel
2
Albumin-Bound Paclitaxel
2
utomilumab
1
toripalimab
1
polyphenon E
1
infigratinib
1
fludarabine phosphate
1
fludarabine
1
epigallocatechin gallate
1
aldesleukin
1
Viusid
1
Vaccines
1
VP-102
1
Therapies, Investigational
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Papillomavirus Infections
×
VP-102
×
Clear all
NCT03981822
2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
105 enrolled
24 charts